• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Canadian Feedyard, LLLP 2/25/14

  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 Dallas District
4040 North Central Expressway
Dallas, Texas 75204-3128 

 

February 25, 2014
 
2014-DAL-WL-03
 
WARNING LETTER
 
UPS OVERNIGHT
 
Kennith L. Thrasher, Manager and Co-Owner
Canadian Feedyard, LLLP
11699 County Road 12
Canadian, Texas 79014-0866
 
Dear Mr. Thrasher:
 
On November 5-7, 2013, the U.S. Food and Drug Administration (FDA) conducted an investigation of your feedyard operation located at 11699 County Road 12, Canadian, Texas 79014-5208. This letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) that we found during our investigation of your operation. You can find the FD&C Act and its associated regulations on the Internet through links on FDA’s web page at www.fda.gov
 
We found that you offered for sale two animals for slaughter as food that were adulterated. Under section 402(a)(2)(C)(ii) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(ii), a food is deemed to be adulterated if it bears or contains a new animal drug that is unsafe under section 512 of the FD&C Act, 21 U.S.C. 360b. Further, under section 402(a)(4) of the FD&C Act, 21 U.S.C. 342(a)(4), a food is deemed to be adulterated if it has been held under insanitary conditions whereby it may have been rendered injurious to health.
 
Specifically, our investigation revealed that on or about May 20, 2013, you sold a steer, identified with ear tag (b)(4), for slaughter as food.  On or about May 20, 2013, (b)(4), slaughtered this animal. United States Department of Agriculture, Food Safety and Inspection Service (USDA/FSIS) analysis of tissue samples collected from this animal identified the presence of 0.406 parts per million (ppm) of flunixin residue in the liver. In addition, our investigation revealed that on or about June 27, 2013, you sold a steer, identified with ear tag (b)(4), for slaughter as food.  On or about June 27, 2013, (b)(4), slaughtered this animal. USDA/FSIS analysis of tissue samples collected from this animal identified the presence of 0.713 ppm of flunixin residue in the liver. FDA has established a tolerance of 125.0 ppb (0.125 ppm) for residues of flunixin in the liver (target tissue) of cattle as codified in Title 21, Code of Federal Regulations (C.F.R.), Section 556.286 (21 C.F.R. 556.286). The presence of this drug in edible tissues from these animals in the amounts stated causes the food to be adulterated within the meaning of section 402(a)(2)(C)(ii) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(ii).
 
Our investigation also found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. For example, you failed to maintain complete treatment records for the steers treated. Food from animals held under such conditions is adulterated within the meaning of section 402(a)(4) of the FD&C Act, 21 U.S.C. 342(a)(4).
 
We also found that you adulterated the new animal drug (b)(4)mg/ml (Flunixin Meglumine, ANADA (b)(4)). Specifically, our investigation revealed that you did not use (b)(4) as directed by the approved labeling or by the servicing veterinarian’s prescription. Use of this drug in this manner is an extralabel use. See 21 C.F.R. 530.3(a).
 
The extralabel use of approved animal or human drugs in animals is allowed under the FD&C Act only if the extralabel use complies with sections 512(a)(4) and (5) of the FD&C Act, 21 U.S.C. 360b(a)(4) and (5), and 21 C.F.R. Part 530, including that the use must be by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian/client/patient relationship. 
 
Our investigation found that you administered (b)(4)mg/ml (Flunixin Meglumine, ANADA (b)(4)) to two steers with ear tag (b)(4) and ear tag (b)(4) without following the route of administration as stated on the approved drug labeling. Your extralabel use of (b)(4) was not under the supervision of a licensed veterinarian, in violation of 21 C.F.R. 530.11(a). Furthermore, your extralabel use of (b)(4) resulted in illegal residues, in violation of 21 C.F.R. 530.11(d). Because your use of this drug was not in conformance with its approved labeling and did not comply with 21 C.F.R. Part 530, you caused the drug to be unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated within the meaning of section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).
 
The above is not intended to be an all-inclusive list of violations. As a producer of animals offered for use as food, you are responsible for ensuring that your overall operation and the food you distribute is in compliance with the law.
 
You should take prompt action to correct the violations described in this letter and to establish procedures to ensure that these violations do not recur. Failure to do so may result in regulatory action without further notice such as seizure and/or injunction. 
 
Our investigation also revealed that on or about January 3, 2013, you provided (b)(4), with a signed Livestock Owner’s Certificate stating that none of the livestock shipped to or delivered to (b)(4) will have an illegal level of drug residues. This signed producer’s certificate covered the steers identified with ear tags (b)(4) and (b)(4), which were found to contain violative flunixin residues. Providing such a false guaranty is prohibited by section 301(h) of the FD&C Act, 21 U.S.C. 331(h). You should take appropriate actions to ensure this violation does not recur.
 
You should notify this office in writing of the steps you have taken to bring your firm into compliance with the law within fifteen (15) working days of receiving this letter. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the time frame within which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.
 
Your written response should be sent to Jeffrey R. Wooley, Compliance Officer, U.S. Food and Drug Administration, 4040 N. Central Expressway, Suite 300, Dallas, Texas 75204. If you have any questions about this letter, please contact Compliance Officer Jeffrey R. Wooley at (214) 253-5251. 
 
Sincerely,
/S/ 
Reynaldo R. Rodriguez, Jr.
Dallas District Director

 

Cc:     
Texas Department of State Health Services
Lewis Ressler
Food Program Manager
Exchange Building
8407 Wall Street
Austin, TX 78754                
 
FSIS District Office 40
Attn: Dr. Jennifer Beasley-McKean, DVM
1100 Commerce Street, Room 516
Dallas, TX 75242-0598
  
Kennith Thrasher, General Manager & Co-Owner
(b)(4)
 
C. R. Bailey, Co-Owner
(b)(4) 
 
L. H. Webb, Co-Owner
(b)(4) 
 
Bobby Webb, Co-Owner
(b)(4) 
 
Gary Deal, Co-Owner
(b)(4)